Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPD

Part of paid clinical trials in Pittsburgh, Pennsylvania.

Sponsor
University of Pittsburgh
Study ID
NCT01745848
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Our primary hypothesis is that Roflumilast (500 μcg, once daily) will significantly decrease surrogate markers of bone metabolism and early cardiovascular disease in individuals with moderate to severe airflow obstruction and a chronic bronchitis phenotype.

Key Dates

Start date
Feb 28, 2013
Status verified
Jul 2017
Primary completion
Jun 30, 2016
Completion
Jun 30, 2016

Study Design

Enrollment
26 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Study Drug
    Roflumilast 500 μcg, once daily, for 30 days

Primary Outcome Measure

Change From Baseline of Systemic Markers of Bone Metabolism (C-terminal Peptide of Type 1 Collagen (CTx) and Amino-terminal Propeptide of Type-1 Procollagen (P1NP)) [ Time Frame: 30 days - measurements at baseline and 30 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Emphysema COPD Research CenterPittsburghPennsylvania15213-

Find similar trials in Pittsburgh, PA

By condition
COPD
By specialty
PulmonologyLung disease
By research site
Emphysema COPD Research Center· Pittsburgh, PA

Related Studies